Gilead Sciences Inc (GILD) performance has elicited mixed reactions among investors given that the stock declined in a market that was showing improvement. However, the company's course towards a $105 price target has been spotted. Despite experiencing high options volume and its Q1 2024 financial reports beating revenue estimates, there seems to be concern over whether its stocks would recover to pre-inflation shock highs of approximately $75. Furthermore, the company's CMO, Merdad Parsey, is set to leave, and its poor Q4 2023 results have led to losses for shareholders. Nonetheless, Raymond James upgraded the company to outperform, and there was a successful HIV treatment trial. Gilead's Urothelial Cancer Study however, failed to meet its primary goal. Unexpectedly, amidst these developments, a surprise big name has entered the weight-loss melee, which could be a potential game changer for Gilead. The FY2024 earnings of GILD are forecasted at $3.85 per share. Furthermore, Gilead has entered an exclusive licensing agreement with Xilio for tumor-activated IL-12 Program and is set to increase its dividend to $0.77.
Gilead Sciences GILD News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Sun, 28 Jul 2024 11:01:26 GMT -
Rating 4
- Innovation 0
- Information 6
- Rumor -3
